CXCR4 and lymphoma: In a recent study by Beider et al. [34], addition of the CXCR4 antagonist BKT140 to rituximab treatment was demonstrated to significantly decrease the number of viable lymphoma cells in Burkitt lymphoma cell line studies as well as in the bone marrow of mice with disseminated Burkitt lymphoma xenografts.